Business Description
Scilex Holding Co
NAICS : 325411
SIC : 2834
ISIN : US80880W2052
Total Employee Number:
34Description
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.03 | |||||
Equity-to-Asset | -0.85 | |||||
Debt-to-Equity | -0.39 | |||||
Debt-to-EBITDA | -0.27 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -10.63 | |||||
Beneish M-Score | -3.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -34.9 | |||||
3-Year EBITDA Growth Rate | -133.3 | |||||
3-Year EPS without NRI Growth Rate | -23 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 173.35 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 27.56 | |||||
9-Day RSI | 42.25 | |||||
14-Day RSI | 49.83 | |||||
3-1 Month Momentum % | 75.66 | |||||
6-1 Month Momentum % | 13.18 | |||||
12-1 Month Momentum % | 39.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.08 | |||||
Quick Ratio | 0.07 | |||||
Cash Ratio | 0.01 | |||||
Days Inventory | 85.17 | |||||
Days Sales Outstanding | 140.6 | |||||
Days Payable | 1985.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.3 | |||||
Shareholder Yield % | -12.92 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 59.65 | |||||
Operating Margin % | -816.77 | |||||
Net Margin % | -1110.17 | |||||
EBITDA Margin % | -1076.87 | |||||
FCF Margin % | -20.47 | |||||
OCF Margin % | -9.74 | |||||
ROA % | -171.31 | |||||
ROIC % | -108.97 | |||||
3-Year ROIIC % | -60.79 | |||||
ROC (Joel Greenblatt) % | -2913.81 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 1.9 | |||||
PS Ratio | 2.24 | |||||
EV-to-EBIT | -0.39 | |||||
EV-to-EBITDA | -0.4 | |||||
EV-to-Revenue | 4.28 | |||||
EV-to-Forward-Revenue | 2.39 | |||||
EV-to-FCF | -20.9 | |||||
Price-to-GF-Value | 1.35 | |||||
Earnings Yield (Greenblatt) % | -256.41 | |||||
FCF Yield % | -12.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SCLX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Scilex Holding Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 33.862 | ||
| EPS (TTM) ($) | -40.47 | ||
| Beta | 3.679 | ||
| 3-Year Sharpe Ratio | -0.06 | ||
| 3-Year Sortino Ratio | -0.1 | ||
| Volatility % | 162.09 | ||
| 14-Day RSI | 49.83 | ||
| 14-Day ATR ($) | 0.932135 | ||
| 20-Day SMA ($) | 8.21175 | ||
| 12-1 Month Momentum % | 39.5 | ||
| 52-Week Range ($) | 2.615093 - 21.337919 | ||
| Shares Outstanding (Mil) | 7.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Scilex Holding Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Scilex Holding Co Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 115 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 23 days | ||
| General meeting for 2026 | 2026-06-24 09:00 | 6.88 (+0.15%) | ||
| First quarter earnings results for 2026 | 2026-05-20 | 3.72 (-0.33%) | ||
| Annual report for 2025 | 2026-04-10 | 4.36 (-3.58%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 11.13 (-7.36%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 11.00 (+10.58%) | ||
| General meeting for 2025 | 2025-06-04 09:00 | 3.41 (+11.63%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 2.61 (+2.95%) | ||
| 0.0285714:1 Stock Split | 2025-04-15 | 4.11 (-8.09%) |
Show
Entries
Scilex Holding Co Frequently Asked Questions
What is Scilex Holding Co(SCLX)'s stock price today?
The current price of SCLX is $7.95. The 52 week high of SCLX is $21.34 and 52 week low is $2.62.
When is next earnings date of Scilex Holding Co(SCLX)?
The next earnings date of Scilex Holding Co(SCLX) is 2026-08-13 Est..
Does Scilex Holding Co(SCLX) pay dividends? If so, how much?
Scilex Holding Co(SCLX) does not pay dividend.
Guru Commentaries on NAS:SCLX
No articles.
Press Release
Articles on Scilex Holding Co
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers